These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30787172)

  • 1. Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition.
    Fischl AS; Wang X; Falcon BL; Almonte-Baldonado R; Bodenmiller D; Evans G; Stewart J; Wilson T; Hipskind P; Manro J; Uhlik MT; Chintharlapalli S; Gerald D; Alsop DC; Benjamin LE; Bhatt RS
    Mol Cancer Ther; 2019 Apr; 18(4):856-867. PubMed ID: 30787172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer.
    Zhang L; Wang X; Bullock AJ; Callea M; Shah H; Song J; Moreno K; Visentin B; Deutschman D; Alsop DC; Atkins MB; Mier JW; Signoretti S; Bhasin M; Sabbadini RA; Bhatt RS
    Clin Cancer Res; 2015 Apr; 21(8):1925-1934. PubMed ID: 25589614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
    Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivation of endothelial cell phosphoinositide 3-kinase β inhibits tumor angiogenesis and tumor growth.
    Azad AK; Zhabyeyev P; Vanhaesebroeck B; Eitzen G; Oudit GY; Moore RB; Murray AG
    Oncogene; 2020 Oct; 39(41):6480-6492. PubMed ID: 32879446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell Carcinomas.
    Dumond A; Montemagno C; Vial V; Grépin R; Pagès G
    Cells; 2021 May; 10(5):. PubMed ID: 34067671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
    Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
    Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of placental growth factor in renal cell carcinoma.
    Bessho H; Wong B; Huang D; Siew EY; Huang D; Tan J; Ong CK; Tan SY; Matsumoto K; Iwamura M; Teh BT
    Anticancer Res; 2015 Jan; 35(1):531-41. PubMed ID: 25550599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.
    Duignan IJ; Corcoran E; Pennello A; Plym MJ; Amatulli M; Claros N; Iacolina M; Youssoufian H; Witte L; Samakoglu S; Schwartz J; Surguladze D; Tonra JR
    Neoplasia; 2011 Jan; 13(1):49-59. PubMed ID: 21245940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.
    Wang X; Solban N; Khanna P; Callea M; Song J; Alsop DC; Pearsall RS; Atkins MB; Mier JW; Signoretti S; Alimzhanov M; Kumar R; Bhasin MK; Bhatt RS
    Oncotarget; 2016 Jul; 7(27):41857-41869. PubMed ID: 27248821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.
    Siemann DW; Brazelle WD; Jürgensmeier JM
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):897-903. PubMed ID: 19215823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1.
    Schmid G; Guba M; Ischenko I; Papyan A; Joka M; Schrepfer S; Bruns CJ; Jauch KW; Heeschen C; Graeb C
    J Cell Biochem; 2007 May; 101(1):259-70. PubMed ID: 17203465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.
    Balthasar S; Bergelin N; Löf C; Vainio M; Andersson S; Törnquist K
    Endocr Relat Cancer; 2008 Jun; 15(2):521-34. PubMed ID: 18509004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
    Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
    Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rac Signaling Drives Clear Cell Renal Carcinoma Tumor Growth by Priming the Tumor Microenvironment for an Angiogenic Switch.
    Goka ET; Chaturvedi P; Lopez DTM; Lippman ME
    Mol Cancer Ther; 2020 Jul; 19(7):1462-1473. PubMed ID: 32371578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.
    Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G
    Oncotarget; 2017 Feb; 8(6):9174-9188. PubMed ID: 27999187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
    Miles KM; Seshadri M; Ciamporcero E; Adelaiye R; Gillard B; Sotomayor P; Attwood K; Shen L; Conroy D; Kuhnert F; Lalani AS; Thurston G; Pili R
    PLoS One; 2014; 9(11):e112371. PubMed ID: 25393540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
    Bridgeman VL; Wan E; Foo S; Nathan MR; Welti JC; Frentzas S; Vermeulen PB; Preece N; Springer CJ; Powles T; Nathan PD; Larkin J; Gore M; Vasudev NS; Reynolds AR
    Mol Cancer Ther; 2016 Jan; 15(1):172-83. PubMed ID: 26487278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.
    Medinger M; Esser N; Zirrgiebel U; Ryan A; Jürgensmeier JM; Drevs J
    Anticancer Res; 2009 Dec; 29(12):5065-76. PubMed ID: 20044618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.
    Matsuki M; Adachi Y; Ozawa Y; Kimura T; Hoshi T; Okamoto K; Tohyama O; Mitsuhashi K; Yamaguchi A; Matsui J; Funahashi Y
    Cancer Sci; 2017 Apr; 108(4):763-771. PubMed ID: 28107584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.